Top

BY Clayton Boldt, Ph.D.

Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division, have advanced a first-in-class therapeutic antibody into a Phase I clinical trial for patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms.

The antibody, known as h8F4, is a T-cell receptor (TCR)-like antibody that can kill...

Visualization of the PR1 peptide target on the surface of AML cells.

BY Scott Merville

Combining two types of drugs that, separately, have extended the lives of people with metastatic melanoma has yielded higher response rates...

BY Scott Merville

V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been recognized for his “services to women’s health” with his appointment...

BY Scott Merville

Improvements in breast cancer treatment over the past five decades have reduced the mortality rate of women with the disease by 40 percent and improved the quality of life of patients, MD Anderson expert Gabriel Hortobagyi, M.D., professor of Breast Medical Oncology noted in a lecture at the 2019 American Society of Clinical Oncology Annual Meeting.

Hortobagyi spoke as this year’s winner of the David A. Karnofsky Memorial Award...

Dr. Gabriel Hortobagyi

BY Scott Merville

MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...

BY Jill Russell, Ph.D.

Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...

BY Ron Gilmore

Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...

BY Clayton R. Boldt, Ph.D.

The Therapeutics Discovery division at MD Anderson Cancer Center has advanced a new small-molecule inhibitor of cancer metabolism to Phase...

BY Jill Russell, Ph.D.

Immunology research to investigate the mechanisms of a new aerosol treatment, which induces an innate immune response to protect against pathogens...

BY Scott Merville

Nobel Laureate Jim Allison, Ph.D., invented immune checkpoint blockade immunotherapy by blocking the CTLA-4 protein on T cells, freeing those...